A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral  -Secretase Inhibitor PF-03084014

(2014) W. A. Messersmith et al.   CLINICAL CANCER RESEARCH

Biomarker and Pharmacologic Evaluation of the  -Secretase Inhibitor PF-03084014 in Breast Cancer Models

(2012) C. C. Zhang et al.   CLINICAL CANCER RESEARCH

Preclinical Analysis of the  -Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia

(2012) J. B. Samon et al.   MOLECULAR CANCER THERAPEUTICS

Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia

(2010) Maddalena Paganin et al.   BLOOD REVIEWS

Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies

(2010) Jon C Aster et al.   JOURNAL OF PATHOLOGY

Evaluation of Selective  -Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

(2010) P. Wei et al.   MOLECULAR CANCER THERAPEUTICS

NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity

(2008) F. Armstrong et al.   BLOOD

Acute lymphoblastic leukaemia

(2008) Ching-Hon Pui et al.   LANCET